

CONFERENCE PROGRAM

Sunday, November 17

5:00 p.m.-7:00 p.m.

OPENING KEYNOTE LECTURES

Salons E-F

5:00 p.m.-6:00 p.m.

Updates in cell therapies

Crystal L. Mackall, Stanford University, Stanford, CA

6:00 p.m.-7:00 p.m.

Story over time, discovery to translation, CTLA-4 and PD-1

Gordon J. Freeman, Dana-Farber Cancer Institute, Boston, MA

7:00 p.m.-9:00 p.m.

OPENING RECEPTION

Back Bay

Monday, November 18

7:00 a.m.-8:00 a.m.

BREAKFAST

Back Bay

8:00 a.m.-10:00 a.m.

PLENARY SESSION 1: INTERSECTION OF SIGNALING PATHWAYS AND IMMUNO-ONCOLOGY

Salons E-F

Session Chair: Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA

8:00 a.m.-8:30 a.m.

STK11/LKB1 and other genomic drivers of a “cold” immune phenotype in NSCLC: Implications for precision immunotherapy

John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30 a.m.-9:00 a.m.

Impact of tumor-resident DC on antitumor immunity

Stefani Spranger

9:00 a.m.-9:30 a.m.

Targeting the RAS-MAPK pathway to enhance immune response

Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

9:30 a.m.-9:45 a.m.

Development of new immune therapy combinations for ovarian cancer using genetically defined organoid platform*

Benjamin Neel, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

9:45 a.m.-10:00 a.m.

Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo*

Bin-Jin Hwang, Duke University, Durham, NC

**Short talk from proffered abstract*

CONFERENCE PROGRAM

10:00 a.m.-10:30 a.m.	COFFEE BREAK Ballroom Foyer
10:30 a.m.-12:30 p.m.	PLENARY SESSION 2: NOVEL CELL THERAPIES Salons E-F Session Chair: Katayoun Rezvani , The University of Texas MD Anderson Cancer Center, Houston, TX
10:30 a.m.-11:030 a.m.	Optimizing T-cell receptor gene therapy for cancer Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA
11:00 a.m.-11:30 a.m.	Engineering natural killer cells for the treatment of cancer Katayoun Rezvani
11:30 a.m.-12:00 p.m.	Understanding resistance to develop next-generation CART for lymphoid malignancies Marco Ruella, University of Pennsylvania, Philadelphia, PA
12:00 p.m.-12:15 p.m.	Development of a transcriptomic T-cell atlas highlights the differential role of T-cell subpopulations in CAR T-cell therapy resistance* Gregory Chen, University of Pennsylvania, Philadelphia, PA
12:15 p.m.-12:30 p.m.	Modulation of integrin CD11b as a novel therapeutic strategy against lung cancer* Terese Geraghty, Rush University, Chicago, IL
12:30 p.m.-3:00 p.m.	LUNCH / POSTER SESSION A Back Bay
3:00 p.m.-5:00 p.m.	PLENARY SESSION 3: ADVERSE EVENTS Salons E-F Session Chair: Antony Rosen , Johns Hopkins University, Baltimore, MD
3:00 p.m.-3:30 p.m.	Checkpoint inhibitor-induced autoimmune diabetes and endocrine syndromes Kevan Herold, Yale School of Medicine, New Haven, CT
3:30 p.m.-4:00 p.m.	Immune checkpoint inhibitor-associated cardiotoxicities: Learning from mice and humans Javid J. Moslehi, Vanderbilt University School of Medicine, Nashville, TN
4:00 p.m.-4:30 p.m.	Autoimmune rheumatic diseases and cancer: An example of natural cancer immunoediting? Antony Rosen
4:30 p.m.-4:45 p.m.	Investigating the mechanisms of immune-related adverse events using engineered animal models* Nikhil Joshi, Yale University, New Haven, CT

**Short talk from proffered abstract*

5:00 p.m.

EVENING ON OWN

Tuesday, November 19

7:00 a.m.-8:00 a.m.

BREAKFAST

Back Bay

8:00 a.m.-10:00 a.m.

PLENARY SESSION 4: EPIGENOMICS OF IMMUNO-ONCOLOGY

Salons E-F

Session Chair: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

8:00 a.m.-8:30 a.m.

Epigenetic therapy—potential efficacy for enhancing immune checkpoint therapy

Stephen B. Baylin

8:30 a.m.-9:00 a.m.

Reprogramming the epigenome for enhancing CAR T-cell antitumor efficacy

Joseph A. Fraietta, University of Pennsylvania, Philadelphia, PA

9:00 a.m.-9:30 a.m.

Molecular programs defining tumor-specific T-cell dysfunction and reprogrammability

Andrea Schietinger, Sloan Kettering Institute, New York, NY

9:30 a.m.-9:45 a.m.

Disrupting enhancers within the core epigenetic program of exhaustion improves T-cell responses and enhances tumor control*

Debattama Sen, Dana-Farber Cancer Institute, Boston, MA

9:45 a.m.-10:05 a.m.

Epigenetic deregulation in LSD1-deficient luminal mammary tumor cells leads to their increased metastasis via reprogramming of the immune microenvironment*

Zhe Li, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

10:00 a.m.-10:30 a.m.

COFFEE BREAK

Ballroom Foyer

**Short talk from proffered abstract*

CONFERENCE PROGRAM

10:30 a.m.-12:30 p.m.	PLENARY SESSION 5: IMAGING AND NEW TECHNOLOGIES Salons E-F Session Chair: Mohammad Rashidian , Harvard Medical School, Cambridge, MA
10:30 a.m.-11:00 a.m.	Noninvasive imaging of immune responses Mohammad Rashidian
11:00 a.m.-11:30 a.m.	Whole-body PD-L1 and PD-1 PET: First-in-human experience David W. Leung, Bristol-Myers Squibb, Princeton, NJ
11:30 a.m.-12:30 p.m.	AI-powered pathology for precision medicine Andrew H. Beck, PathAI, Boston, MA (not eligible for CME credit)
12:00 p.m.-12:15 p.m.	Irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic antitumor immunity* Irving Allen, Virginia Tech, Blacksburg, VA
12:30 p.m.-2:30 p.m.	LUNCH ON OWN
2:30 p.m.-4:30 p.m.	PLENARY SESSION 6: TUMOR EVOLUTION AND THE TUMOR MICROENVIRONMENT Salons E-F Session Chair: Christina Leslie , Sloan Kettering Institute, New York, NY
2:30 p.m.-3:00 p.m.	The impact of tumor microenvironment on clonal evolution in cancer Samra Turajlic, The Francis Crick Institute, London, United Kingdom
3:00 p.m.-3:30 p.m.	Myeloid cell control of tumor immunity Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
3:30 p.m.-4:00 p.m.	Chromatin state and scRNA-seq analysis defines a common differentiation trajectory towards T-cell exhaustion Christina Leslie
4:00 p.m.-4:15 p.m.	Loss of PD-1 promotes antitumor immunity by improving functions of both PD-1+ and PD-1- CD8+ T cells in the tumor microenvironment* Kristen Pauken, Harvard Medical School, Boston, MA
4:15 p.m.-4:30 p.m.	Active and quiescent tertiary lymphoid structures, differentiated using FOXP1 expression, play a role in immunity to breast cancer* Pushpamali De Silva, Institut Jules Bordet, Brussels, Belgium
4:30 p.m.-7:00 p.m.	RECEPTION / POSTER SESSION B Back Bay

**Short talk from proffered abstract*

Wednesday, November 20

7:00 a.m.-8:00 a.m.	BREAKFAST Arlington & Fairfield
8:00 a.m.-10:00 a.m.	PLENARY SESSION 7: INTERACTION BETWEEN THE MICROBIOME AND IMMUNITY, SYSTEMIC AND LOCAL RESPONSES Salons E-F Session Chair: Jennifer A. Wargo , The University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-8:30 a.m.	Colorectal cancer and the microbiota Wendy S. Garrett, Harvard T.H. Chan School of Public Health, Boston, MA
8:30 a.m.-9:00 a.m.	The unsuspected role of gut microbiota in cancer therapies: Antigen mimicry between intestinal phage and tumor antigens Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France
9:00 a.m.-9:30 a.m.	The role of the microbiome in response and toxicity to cancer therapy Jennifer A. Wargo
10:00 a.m.-10:30 a.m.	COFFEE BREAK Ballroom Foyer
10:30 a.m.-12:30 p.m.	PLENARY SESSION 8: INTERFACE OF GENETICS, ANTIGENS, AND IMMUNO-ONCOLOGY, INCLUDING VACCINES, ADJUVANTS, AND BIOMARKERS Salons E-F Session Chair: Luis A. Diaz , Memorial Sloan Kettering Cancer Center, New York, NY
10:30 a.m.-11:00 a.m.	T cells as a drug for the personalized immunotherapy of cancer Steven A. Rosenberg, National Cancer Institute, Bethesda, MD
11:00 a.m.-11:30 a.m.	Tumor-intrinsic drivers of response and resistance to checkpoint blockade in MRD tumors Luis A. Diaz
11:30 a.m.-11:45 a.m.	Antigen dominance hierarchies shape tumor T cell phenotypes and immunotherapy responses* Megan Burger, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
11:45 a.m.-12:00 p.m.	Genomic landscape of immunotherapy resistance in lung cancer* Denise Lau, Tempus, Chicago, IL

**Short talk from proffered abstract*

CONFERENCE PROGRAM

12:00 p.m.-12:15 p.m.	Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination* Joseph Antonios, Yale School of Medicine, New Haven, CT
12:15 p.m.-12:30 p.m.	Emergence of quality metrics for neoantigens: Dissimilarity to the self-proteome as a novel determinant of immunogenicity* Lee Richman, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
12:30 p.m.	CONCLUDING REMARKS Salons E-F

**Short talk from proffered abstract*